Cancer-drug associations: A complex system

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Dalkic, Ertugrul ^a,b   Wang, Xuewei ^a,b   Wright, Neil ^a,b   Chan, Christina ^a,b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University   (United States)

^c Michigan State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; LENALIDOMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PROCARBAZINE; SORAFENIB; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DRUG APPROVAL; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LINEAR REGRESSION ANALYSIS; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; MYELOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; SARCOMA; SKIN CANCER; STOMACH CANCER; TESTIS CANCER; UTERINE CERVIX CANCER; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; NEOPLASM; SYSTEMS THEORY; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG APPROVAL; NEOPLASMS; SYSTEMS THEORY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956331411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010031     Document Type: Article

References (15)

1. Miniño AM, Heron MP, Murphy SL, Kochanek KD. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System (2007) Deaths: final data for 2004. Natl Vital Stat Rep 55: 1-119.
2. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
3. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
4. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R (2007) Network analysis of FDA approved drugs and their targets. Mt Sinai J Med 74: 27-32.
5. Sakharkar MK, Li P, Zhong Z, Sakharkar KR (2008) Quantitative analysis on the characteristics of targets with FDA approved drugs. Int J Biol Sci 4: 15-22.
6. Nacher JC, Schwartz JM (2008) A global view of drug-therapy interactions. BMC Pharmacol 8: 5.
7. Barabasi AL (2007) Network Medicine-From Obesity to the "Diseasome". N Engl J Med 357: 404-407.
8. Hopkins AL (2007) Network pharmacology. Nat Biotechnol 25: 1110-1111.
9. American Cancer Society (2001-2008) Cancer Facts & Figures. Atlanta: American Cancer Society.
10. Newman MEJ (2003) The structure and function of complex networks. SIAM Review 45: 167-256.
11. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, et al. (1986) Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1: 765-767.
12. Testa JR, Siegfried JM (1992) Chromosome abnormalities in human non-small cell lung cancer. Cancer Res 52: 2702-2706.
13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
14. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
15. Best DJ, Roberts DE (1975) Algorithm AS 89: The Upper Tail Probabilities of Spearman's rho. Applied Statistics 24: 377-379.